Highlights

  • Racura Oncology Limited (ASX: RAC) lodged an Appendix 3H dated 13 July 2026 confirming that 270,000 RACAL options expired unexercised on 12 July 2026.
  • The options carried an exercise price of $4.76 and no consideration was paid by the company for their cessation.
  • Because the options were never exercised, no new shares were created, so this specific event adds no dilution for existing holders.
  • Ordinary fully paid shares on issue stand at 196,068,940 following the change, essentially unchanged by the expiry.
  • Other unquoted option classes remain on issue, so investors should treat this notice as administrative rather than a signal about business performance.

For shareholders in a clinical-stage biopharmaceutical company, not every market announcement is about trial data or a new partnership. Some notices are purely mechanical, describing changes to the capital structure rather than the science or strategy behind it. The latest filing from Racura Oncology Limited (ASX:RAC) falls squarely into that category. On 13 July 2026 the company lodged an Appendix 3H, confirming the cessation of a small parcel of options that expired without being exercised.

For existing holders of ASX: RAC, the practical takeaway is refreshingly simple, and this article is written from that shareholder perspective. The event changes very little. It does not raise cash, it does not issue new shares, and it does not alter the number of ordinary shares already in the market. Yet capital-structure notices are still worth understanding, because share count, dilution and the pool of options on issue determine how much of the company each investor actually owns. This piece walks through what the Appendix 3H says and why the expiry is immaterial to Racura Oncology's day-to-day operations.

Inside the Announcement

The Appendix 3H is a standardised ASX form used to notify the market that securities have ceased to exist. In Racura Oncology's case, the form records that 270,000 options under the code RACAL, described as "OPTION EXPIRING 12-JUL-2026 EX $4.76", ceased on 12 July 2026. The reason is straightforward: the options expired without being exercised or converted into shares.

Three details matter here. First, the exercise price attached to these options was $4.76, the amount a holder would have needed to pay per option to convert it into an ordinary share before the expiry date. Second, no consideration was paid by the company in connection with the cessation; Racura Oncology did not buy the options back, and they simply reached their expiry date and lapsed. Third, following the change, the company's issued capital shows 196,068,940 ordinary fully paid shares on issue under the RAC ordinary fully paid line, while the RACAL option line now shows a balance of zero.

Put together, these facts describe a clean, routine housekeeping event. A defined class of options had a defined life, that life ended on 12 July 2026, and the register has been updated to reflect their removal. There is no accompanying transaction, no capital raising and no change of control.

Background: Racura Oncology and RC220

To place the announcement in context, it helps to recall what Racura Oncology actually does. The company describes itself as a Phase 3 clinical-stage biopharmaceutical business with a mission to "silence cancer". Its lead asset is (E,E)-bisantrene, a small molecule anticancer agent that primarily acts through G-quadruplex DNA and RNA binding, silencing MYC, an important regulator of cancer growth. RC220 is a proprietary formulation of (E,E)-bisantrene developed by Racura, and it sits at the centre of the company's three clinical programs.

Those programs span a Phase 3 program in acute myeloid leukaemia targeting c-MYC silencing, the HARNESS-1 Phase 1 trial combining RC220 with Tagrisso in EGFR-mutant non-small cell lung cancer, and the CPACS Phase 1 program combining RC220 with doxorubicin in solid tumours. The company is led by Chief Executive and Managing Director Dr Daniel Tillett, with Dr Peter Smith as Executive Chair.

None of that pipeline activity is touched by the options expiry. The Appendix 3H is a capital-structure notice, entirely separate from the clinical and commercial work that drives the investment case. Understanding the pipeline simply reminds shareholders that the value of the business rests on trial progress and partnering, not on the lapse of a single option class.

The Shareholder View: Dilution, Share Count and What Actually Changes

For an existing shareholder, the most important question about any options event is a simple one: does this change how many shares exist, and therefore how much of the company I own? Here, the answer is no.

Why there is no new dilution from this event

Dilution occurs when a company issues new shares, which spreads ownership, earnings and voting rights across a larger base. Options can be dilutive, but only when they are exercised, because exercising an option is what brings a new share into existence. In this case the 270,000 RACAL options were never exercised. They reached their expiry date at an exercise price of $4.76 and lapsed. Because no exercise took place, no new shares were created, so there is no additional dilution to existing holders from this specific event. If anything, the expiry removes a set of potential future shares that will now never be issued from this class.

The share count remains essentially unchanged

The corollary is that the ordinary share count barely moves. After the change, Racura Oncology reports 196,068,940 ordinary fully paid shares on issue. That figure reflects the shares that already existed before the expiry; the lapse did not add to it or subtract from it. For a shareholder tracking their proportional stake, the denominator is effectively the same today as before the filing. This is why the company frames the notice as routine.

Other option classes remain on issue

One nuance is worth flagging for completeness. The expiry of the RACAL options does not clear out every option on Racura Oncology's register. The company retains a number of other unquoted option classes on issue across various codes, exercise prices and expiry dates. Those instruments are context rather than cause for concern in this filing, but they do represent potential future dilution if, and only if, they are later exercised. Today's Appendix 3H concerns only the RACAL parcel and creates no dilution of its own.

What It Could Mean for ASX: RAC

From a strictly administrative standpoint, the practical effect of this announcement on ASX: RAC is minimal. The company's capital structure is now marginally tidier, with one expired option class removed and the ordinary share count confirmed at 196,068,940. That is useful for anyone modelling the company, because a clear, current share count is the foundation for any per-share calculation.

It is equally important to be clear about what the expiry is not. It is not a cash event, because no money changed hands and the lapse did not raise funds. It is not evidence of improving performance, because options expiring out of the exercise window says nothing about clinical progress, revenue or strategy. And it offers no basis for inferring the share price, because the filing carries no market-pricing information. The sensible reading is narrow: a capital-structure update that confirms the current share count and removes a lapsed instrument, nothing more.

Limitations and Key Risks

The options expiry itself is immaterial to Racura Oncology's operations, but the broader investment case still carries the risks common to clinical-stage biopharmaceutical companies, and shareholders should weigh them independently of this filing.

Clinical risk is foremost. RC220 is being evaluated across Phase 3 and Phase 1 programs, and early-stage trials can fail to demonstrate efficacy or encounter safety issues even after encouraging beginnings. Regulatory risk follows, because approvals are never guaranteed and timelines can extend well beyond expectations. Funding risk is material for any pre-revenue biotech, as advancing multiple oncology programs is capital-intensive and future raisings could themselves cause dilution separate from anything in this announcement. Execution risk covers running multicentre trials across several jurisdictions, and commercialisation risk reflects the reality that even an approved therapy must still secure market access, reimbursement and adoption.

On the specific matter at hand, two points bear repeating. First, this options expiry is administrative and immaterial to the company's operations; it should not be read as good or bad news about the science. Second, other unquoted option classes remain on issue, so the potential for future dilution from those instruments continues to exist if they are eventually exercised.

What Investors May Watch Next

Because the Appendix 3H is administrative, the more meaningful signals for shareholders will come from Racura Oncology's operational calendar rather than its option register. Investors may watch progress across the three clinical programs, including the Phase 3 AML work, the HARNESS-1 trial and the CPACS study, as these are the developments that genuinely move the investment case.

On the capital-structure side, shareholders can continue to monitor the total shares on issue, currently 196,068,940, and note any future Appendix 3B or Appendix 3H filings that would signal shares being issued or further options ceasing. Any exercise of the remaining unquoted option classes would be disclosed through the usual ASX channels, and tracking those notices is the practical way to stay current on the company's evolving share count.

Conclusion

The lapse of 270,000 RACAL options is, for shareholders in Racura Oncology Limited (ASX: RAC), one of the least dramatic announcements it could make. The options expired unexercised on 12 July 2026 at an exercise price of $4.76, no consideration was paid, and the Appendix 3H dated 13 July 2026 records their removal. Because the options were never exercised, no new shares were created, so there is no additional dilution from this event, and the ordinary share count stands at 196,068,940.

The right frame is administrative. This filing neither generated cash nor changed the fundamentals, and it offers no read on the share price or business performance. For existing holders of ASX: RAC, the ownership arithmetic is essentially untouched, and attention is better directed at the clinical pipeline than at a single expired parcel. Clear, current share-count information is valuable in its own right, and that is what this notice provides.